Actively Recruiting
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-16
60
Participants Needed
7
Research Sites
155 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
CONDITIONS
Official Title
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 or older
- Pathologic confirmation of diffuse pleural mesothelioma, gastroesophageal carcinoma (adenocarcinoma or squamous cell carcinoma), or urothelial carcinoma
- PD-L1 CPS 651 (using clone 73-10, DAKO)
- HER2 negative status confirmed by immunohistochemistry and in situ hybridization
- Metastatic or advanced/unresectable disease with specific prior treatment conditions depending on cancer type
- Confirmation of MTAP deletion by immunohistochemistry or next-generation sequencing on tumor tissue
- Measurable disease by RECIST v1.1 or modified RECIST for mesothelioma
- No contraindications to receiving standard-of-care agents for respective cancers
- Karnofsky Performance Status 6570 or ECOG performance status less than 1
- Female participants of child-bearing potential must have a negative pregnancy test and agree to use effective contraception during and after the study
- Male participants must agree to use condoms during and after the study and refrain from sperm donation
- Recovery from prior therapy adverse effects to baseline or grade 1, except specific allowed conditions
- Adequate hematologic, renal, and hepatic function as defined by specific laboratory values
- Signed informed consent form
You will not qualify if you...
- Prior treatment with PRMT5 inhibitors or MAT2A inhibitors
- Symptomatic central nervous system metastases
- Recent palliative radiation therapy or stereotactic radiosurgery within specified time frames
- Major surgery within 3 weeks before starting study drug, excluding minor procedures
- Certain cardiac conditions including unstable angina, recent myocardial infarction, congestive heart failure class 3 or higher, prolonged QTc, or history of Long QT Syndrome
- Child-Pugh class C liver cirrhosis
- Any ongoing medical illness that would prevent study participation per investigator discretion
- Inability to take oral medications or conditions affecting absorption of BMS-986504
- Need for medications that strongly affect cytochrome P450 3A4 or P-glycoprotein that cannot be changed
- Detectable viral load of HIV, hepatitis B, or hepatitis C unless effectively treated and undetectable
- Active infection requiring intravenous antibiotics
- Pregnancy or breastfeeding
- Presence of another malignancy that could interfere with study assessments, except certain stable or treated malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
M
Michael Offin, MD
CONTACT
S
Steven Maron, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here